A study of 314 patient showed that VeriStrat is predictive of survival benefit in patients with squamous cell carcinoma of the head and neck (SCCHN) treated with epidermal growth factor inhibitors (EGFRIs). In the study, VeriStrat was used to classify outcomes in patients with SCCHN who were treated with gefitinib (G), erlotinib and bevacizumab (E/B), cetuximab (C), or palliative chemotherapy (PC). Gefitinib, erlotinib and cetuximab are EGFRIs with activity in SCCHN. Results from the study show that among patients treated with EGFRIs, VeriStrat predicted an overall survival benefit. VeriStrat did not classify survival outcomes in patients treated with palliative chemotherapy.
Listen to Ezra Cohen, MD, associate professor of medicine at the University of Chicago, and a study investigator, discuss the findings of this study and what they may mean for community-based oncologists.
(Right click to save and download podcast)